Ajooni Biotech Valuation
| AJOONI Stock | 7.42 0.04 0.54% |
At this time, the firm appears to be overvalued. Ajooni Biotech shows a prevailing Real Value of USD6.76 per share. The current price of the firm is USD7.42. Our model approximates the value of Ajooni Biotech from analyzing the firm fundamentals such as Current Valuation of 754.71 M, return on equity of 0.0354, and Profit Margin of 0.03 % as well as examining its technical indicators and probability of bankruptcy.
Price Book 1.7264 | Enterprise Value 754.7 M | Enterprise Value Ebitda 17.0787 | Price Sales 0.9132 | Trailing PE 35.4091 |
Overvalued
Today
Please note that Ajooni Biotech's price fluctuation is slightly risky at this time. Calculation of the real value of Ajooni Biotech is based on 3 months time horizon. Increasing Ajooni Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Ajooni Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Ajooni Stock. However, Ajooni Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 7.42 | Real 6.76 | Hype 7.42 | Naive 7.51 |
The real value of Ajooni Stock, also known as its intrinsic value, is the underlying worth of Ajooni Biotech Company, which is reflected in its stock price. It is based on Ajooni Biotech's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Ajooni Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Ajooni Biotech Limited helps investors to forecast how Ajooni stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Ajooni Biotech more accurately as focusing exclusively on Ajooni Biotech's fundamentals will not take into account other important factors: Ajooni Biotech Cash |
|
Ajooni Biotech Total Value Analysis
Ajooni Biotech Limited is presently estimated to have takeover price of 754.71 M with market capitalization of 774.1 M, debt of 21.68 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Ajooni Biotech fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
754.71 M | 774.1 M | 21.68 M |
Ajooni Biotech Investor Information
The company has price-to-book (P/B) ratio of 1.73. Some equities with similar Price to Book (P/B) outperform the market in the long run. Ajooni Biotech had not issued any dividends in recent years. The entity had 5:1 split on the 7th of October 2022. Based on the key indicators obtained from Ajooni Biotech's historical financial statements, Ajooni Biotech Limited is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Ajooni Biotech Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Ajooni Biotech has an asset utilization ratio of 168.35 percent. This suggests that the Company is making USD1.68 for each dollar of assets. An increasing asset utilization means that Ajooni Biotech Limited is more efficient with each dollar of assets it utilizes for everyday operations.Ajooni Biotech Profitability Analysis
The company reported the revenue of 800.01 M. Net Income was 21.61 M with profit before overhead, payroll, taxes, and interest of 87.45 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Ajooni Biotech's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Ajooni Biotech and how it compares across the competition.
About Ajooni Biotech Valuation
The stock valuation mechanism determines Ajooni Biotech's current worth on a weekly basis. Our valuation model uses a comparative analysis of Ajooni Biotech. We calculate exposure to Ajooni Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Ajooni Biotech's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 58 M | 53.5 M |
Ajooni Biotech Quarterly Retained Earnings |
|
Complementary Tools for Ajooni Stock analysis
When running Ajooni Biotech's price analysis, check to measure Ajooni Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ajooni Biotech is operating at the current time. Most of Ajooni Biotech's value examination focuses on studying past and present price action to predict the probability of Ajooni Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ajooni Biotech's price. Additionally, you may evaluate how the addition of Ajooni Biotech to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |